期刊
JOURNAL OF NEUROSURGERY
卷 133, 期 3, 页码 655-663出版社
AMER ASSOC NEUROLOGICAL SURGEONS
DOI: 10.3171/2019.5.JNS19364
关键词
experimental therapeutics; glioblastoma; GBM; glioma stem cells; GSC; intratumoral heterogeneity; oncology
资金
- NIH/National Cancer Institute [P01 CA163205, R21 CA175875]
- NIH/National Institute of Neurological Disorders and Stroke [R01 NS083767, R01 NS087913]
- University of Alabama Medical Scientist Training Program
Glioblastoma (GBM), the most common primary malignant brain tumor in adults, is associated with significant morbidity and mortality despite maximal safe resection followed by chemo- and radiotherapy. GBMs contain self-renewing, tumorigenic glioma stem cells that contribute to tumor initiation, heterogeneity, therapeutic resistance, and recurrence. Intratumoral heterogeneity (ITH) of GBMs is also a major contributing factor to poor clinical outcomes associated with these high-grade glial tumors. Herein, the authors summarize recent discoveries and advances in the molecular and phenotypic characterization of GBMs with particular focus on ITH. In so doing, they attempt to highlight recent advances in molecular signatures/properties and metabolic alterations in an effort to clarify translational implications that may ultimately improve clinical outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据